검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Monoclonal antibody |
Overview Company | Sung-Soo Park |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeting FXIIa, garadacimab acts upstream in the kallikrein-kinin pathway |
MoA Biomarker | biomarkers are strong predictors of accelerated monoclonal antibody clearance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway.. Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of bradykinin-mediated angioedema affecting the skin, gastrointestinal tract, and upper airway. Despite the availability of several prophylactic therapies, the… |
Clinical Primary efficacy | ORR 24% |
Clinical ORR | 24% |
Clinical PFS | 41 |
Clinical OS | 63.1 |
Clinical Result source | ClinicalTrials.gov NCT00612430 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Monoclonal antibody |
Overview Company | Sung-Soo Park |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Multiple Myeloma, Relapsed; Multiple Myeloma (MM) |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeting FXIIa, garadacimab acts upstream in the kallikrein-kinin pathway |
MoA Biomarker | biomarkers are strong predictors of accelerated monoclonal antibody clearance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Garadacimab and the future of hereditary angioedema prophylaxis: a step upstream in the bradykinin pathway.. Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterized by recurrent, potentially life-threatening episodes of bradykinin-mediated angioedema affecting the skin, gastrointestinal tract, and upper airway. Despite the availability of several prophylactic therapies, the… |
Clinical Primary efficacy | ORR 24% |
Clinical ORR | 24% |
Clinical PFS | 41 |
Clinical OS | 63.1 |
Clinical Result source | ClinicalTrials.gov NCT00612430 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교